Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial

Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial

<p><strong>Aims</strong></p> <p>To evaluate 1,5‐anhydroglucitol (1,5‐AG) according to clinical outcomes and assess the effects of glucose‐ and blood pressure‐lowering interventions on change in 1,5‐AG levels in people with type 2 diabetes.</p> <p><strong...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Selvin, E, Wang, D, McEvoy, JW, Juraschek, SP, Lazo, M, Hamet, P, Cooper, ME, Marre, M, Williams, B, Harrap, S, Chalmers, J, Woodward, M
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Wiley 2019

Παρόμοια τεκμήρια

Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial
ανά: Rahman, F, κ.ά.
Έκδοση: (2019)

Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism
ανά: Man Li, κ.ά.
Έκδοση: (2017-06-01)

Data for serum 1,5 anhydroglucitol concentration in different populations
ανά: Marciane Welter, κ.ά.
Έκδοση: (2018-10-01)

The clinical potential of 1,5-anhydroglucitol as biomarker in diabetes mellitus
ανά: Haiying Xu, κ.ά.
Έκδοση: (2024-10-01)

The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients
ανά: Eduardo Moraes Leao Peixoto, κ.ά.
Έκδοση: (2014-10-01)

The use of 1,5 anhydroglucitol level as a clinical test to differentiate subtypes of diabetes
ανά: Owen, K, κ.ά.
Έκδοση: (2009)

Intensive glucose lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial
ανά: Ohkuma, T, κ.ά.
Έκδοση: (2019)

Pemeriksaan 1,5-Anhydroglucitol, Suatu Hal Baru dalam Pemeriksaan Prediabetes
ανά: Reza Febryan
Έκδοση: (2024-03-01)

Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes
ανά: Ha Yeong Yoo, κ.ά.
Έκδοση: (2015-12-01)

The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications
ανά: Huijuan Xu, κ.ά.
Έκδοση: (2024-05-01)

Side-effects and tolerability of combination blood pressure lowering according to blood pressure levels – an analysis of the PROGRESS and ADVANCE trials
ανά: Atkins, A, κ.ά.
Έκδοση: (2017)

Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
ανά: Pal, A, κ.ά.
Έκδοση: (2010)

History of lower-limb complications and risk of cancer death in people with type 2 diabetes
ανά: Kamel Mohammedi, κ.ά.
Έκδοση: (2021-01-01)

Prognostic Value of Serum 1,5-anhydroglucitol Levels in Patients with Acute Myocardial Infarction
ανά: Yijia Wang, κ.ά.
Έκδοση: (2022-12-01)

Relationship of glycemic control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance
ανά: Thyparambil Aravindakshan Pramodkumar, κ.ά.
Έκδοση: (2016-01-01)

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
ανά: Zoungas, S, κ.ά.
Έκδοση: (2009)

1,5-anhydroglucitol in diabetes: its role in diagnostics, screening, glycemic status assessment, and the prediction of complications
ανά: V. V. Klimontov, κ.ά.
Έκδοση: (2020-08-01)

Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol
ανά: Ji-Eun Lee
Έκδοση: (2015-06-01)

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
ανά: Patel, A, κ.ά.
Έκδοση: (2008)

Lowering blood pressure reduces renal events in type 2 diabetes.
ανά: de Galan, B, κ.ά.
Έκδοση: (2009)

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
ανά: Perkovic, V, κ.ά.
Έκδοση: (2013)

1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus
ανά: Masahiro Usui, κ.ά.
Έκδοση: (2020-09-01)

Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE‐ON study
ανά: Rådholm, K, κ.ά.
Έκδοση: (2018)

Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome
ανά: Gong Su, κ.ά.
Έκδοση: (2020-05-01)

Estimating individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes
ανά: Woodward, M, κ.ά.
Έκδοση: (2016)

Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis
ανά: Kenji Tanaka, κ.ά.
Έκδοση: (2021-08-01)

Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study
ανά: Mohammedi, K, κ.ά.
Έκδοση: (2016)

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
ανά: Mohammedi, K, κ.ά.
Έκδοση: (2017)

Saliva 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with type 2 diabetes
ανά: Jian Zhou, κ.ά.
Έκδοση: (2021-03-01)

1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
ανά: Hannah Seok, κ.ά.
Έκδοση: (2015-04-01)

Evaluation of 1,5-Anhydroglucitol as a Biomarker for Type 2 Diabetes Mellitus in Patients without Overt Nephropathy
ανά: Luiza Cristina Gobor, κ.ά.
Έκδοση: (2021-10-01)

Detection of 1,5-anhydroglucitol as a Biomarker for Diabetes Using an Organic Field-Effect Transistor-Based Biosensor
ανά: Hiroyuki Furusawa, κ.ά.
Έκδοση: (2018-08-01)

Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker
ανά: Ben A. Kappel, κ.ά.
Έκδοση: (2021-06-01)

Association between 1,5-Anhydroglucitol and Acute C Peptide Response to Arginine among Patients with Type 2 Diabetes
ανά: Yun Shen, κ.ά.
Έκδοση: (2020-01-01)

Nonlinear association of 1,5-anhydroglucitol with the prevalence and severity of coronary artery disease in chinese patients undergoing coronary angiography
ανά: Ruiyue Yang, κ.ά.
Έκδοση: (2022-09-01)

Evaluation of serum 1,5-anhydroglucitol levels as hyperglycemic indicator in patients with newly diagnosed type 2 diabetes mellitus
ανά: Ashok Vanagamudi, κ.ά.
Έκδοση: (2022-01-01)

Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes
ανά: Mohammedi, K, κ.ά.
Έκδοση: (2016)

The relationship between serum 1,5-anhydroglucitol and adverse outcomes in acute coronary syndrome with and without chronic kidney disease patients
ανά: Yijia Wang, κ.ά.
Έκδοση: (2024-07-01)

1,5-Anhydroglucitol promotes pre-B acute lymphocytic leukemia progression by driving glycolysis and reactive oxygen species formation
ανά: Huasu Zhu, κ.ά.
Έκδοση: (2023-02-01)

The impact of level of education on vascular events and mortality in patients with type 2 Diabetes mellitus: results from the ADVANCE study
ανά: Blomster, J, κ.ά.
Έκδοση: (2017)